For results that have...

But don't include...


Click to add/remove this article to your list of 'My Favorites' A Diabetes-specific Enteral Formula Containing Isomaltulose Has a Lower Glycemic Index Value Compared to a Standard Enteral Formula

Year: 2007

Abstract Number: 1782-P

Authors: ANNE L. FALK, MARYAM K. OLESEN, YOSHIMI YOSHIMOTO, St. Louis Park, MN, Gland, Switzerland, Tokyo, Japan

Results: The type and amount of carbohydrate, protein and fat in enteral nutrition formulas affects the glycemic index (GI). Rapidly digested carbohydrates (glucose and maltodextrin) increase GI, whereas, slow-release carbohydrates (e.g., isomaltulose) decrease GI. Therefore, we evaluated the postprandial blood glucose response of enteral formulas by comparing the GI of a diabetes-specific formula containing isomaltulose (Resource GlucoPal, Novartis Medical Nutrition) to a standard formula containing maltodextrin (Isocal RTU, Novartis Medical Nutrition). In a randomized, crossover design study, 2 products were tested in 12 healthy volunteers. After an overnight fast, volunteers consumed a portion of the test product containing 25g of available carbohydrate or the reference feed (25g glucose in 200ml). Postprandial blood glucose levels were measured for 2 h after intake and incremental area under the curve (AUC) was calculated for both the test products and reference feed. The GI of the test products was determined by dividing the AUC of the test products by the AUC of the reference feed. The diabetes-specific product, Resource GlucoPal, had a GI value of <55, categorizing it as a low GI formula. Resource GlucoPal had a lower GI value compared to Isocal RTU (GI±SD; 43±7 vs 76±8, respectively; p=0.02). The data indicate that diabetes-specific formulas with slow-release carbohydrates provide better glycemic control compared to standard formulas. The results also indicate the use of GI values may be more appropriate than total carbohydrate content in predicting glycemic response and may help improve the nutritional management of patients with diabetes.